Slingshot members are tracking this event:

Interim Analysis Results from Pfizer's (PFE) Phase 3 BEACON CRC Trial of BRAFTOVI (Encorafenib), MEKTOVI (Binimetinib) and Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Clinical Data The BRAFTOVI Triplet showed a median OS of 9.0 months for patients treated with the Triplet, compared to 5.4 months for Control ([HR 0.52, (95% CI 0.39-0.70), p<0.0001]). The BRAFTOVI Triplet also demonstrated a significantly improved ORR of 26% (95% CI: 18%, 35%) compared to 2% (95% CI: 0%, 7%) for Control (p<0.0001).
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 30, 2019
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Mektovi, Encorafenib, Braftovi, Phase 3 Study, Binimetinib, Colorectal Cancer